Additionally, we found that the proportion of CD8+ T and NK cells decreased in AML; accordingly, there exists potential for a general diagnostic method to help identify effective immunotherapy strategies by targeting CD8+ T and NK cells. The gene discussed is CD8A; the disease is acute myeloid leukemia.